Loading...
Market
Will more than 1 million units of FluMist nasal spray be sold by March 31, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
AstraZeneca sales reports and industry analysis
Story
FDA Approves First-of-Its-Kind FluMist Nasal Spray for Self-Administration
Sep 20, 2024, 08:15 PM
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's FluMist nasal spray influenza vaccine for self-administration, making it the first of its kind. This approval marks the first time a flu vaccine can be administered at home without the need for a healthcare provider. The FluMist vaccine, which contains a weakened live virus, is designed for individuals aged 2 to 49 and covers influenza virus subtypes A and B. This development is part of a broader effort by the FDA to expand consumer access to medicines and reduce healthcare costs and barriers. The vaccine will be available through a third-party pharmacy, where individuals will complete a screening and eligibility assessment before ordering. The FluMist nasal spray will be available starting next season.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 500,000 • 25%
500,000 to 1 million • 25%
1 million to 2 million • 25%
More than 2 million • 25%
Less than 100,000 units • 25%
100,000 to 500,000 units • 25%
500,000 to 1 million units • 25%
More than 1 million units • 25%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%